The clonoSEQ® Watch Registry
Trial ID or NCT#
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
- 1. Patients must be able to provide written informed consent 2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care 3. Age ≥ 18 years; 4. Documented hematologic malignancy (any of the below): 1. MM 2. ALL (B and T-cell subtypes) 3. B-cell NHL (all sub types) 4. CLL 5. Other lymphoid malignancies (upon review and approval by study chair)
- Patients must not meet any of the following criteria in order to be enrolled into the study: 1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol 2. A decision has been made by the treating provider to not use the clonoSEQ Assay as part of routine clinical care
Contact us to find out if this trial is right for you.